Show simple item record

dc.contributor.authorZhang, J
dc.contributor.authorShrivastava, S
dc.contributor.authorCleveland, RO
dc.contributor.authorRabbitts, TH
dc.date.accessioned2019-10-21T09:26:15Z
dc.date.issued2019-03-20
dc.identifier.citationACS applied materials & interfaces, 2019, 11 (11), pp. 10481 - 10491
dc.identifier.issn1944-8244
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3384
dc.identifier.eissn1944-8252
dc.identifier.doi10.1021/acsami.8b21398
dc.description.abstractCellular membranes are, in general, impermeable to macromolecules (herein referred to as macrodrugs, e.g., recombinant protein, expression plasmids, or mRNA), which is a major barrier for clinical translation of macrodrug-based therapies. Encapsulation of macromolecules in lipid nanoparticles (LNPs) can protect the therapeutic agent during transport through the body and facilitate the intracellular delivery via a fusion-based pathway. Furthermore, designing LNPs responsive to stimuli can make their delivery more localized, thus limiting the side effects. However, the principles and criteria for designing such nanoparticles remain unclear. We show that the thermodynamic state of the lipid membrane of the nanoparticle is a key design principle for acoustically responsive fusogenic nanoparticles. We have optimized a cationic LNP (designated LNPLH) with two different phase transitions near physiological conditions for delivering mRNA. A bicistronic mRNA encoding a single domain intracellular antibody fragment and green fluorescent protein (GFP) was introduced into a range of human cancer cell types using LNPLH, and the protein expression was measured via fluorescence corresponding to the GFP expression. The LNPLH/mRNA complex demonstrated low toxicity and high delivery, which was significantly enhanced when the transfection occurred in the presence of acoustic shock waves. The results suggest that the thermodynamic state of LNPs provides an important criterion for stimulus responsive fusogenic nanoparticles to deliver macrodrugs to the inside of cells.
dc.formatPrint-Electronic
dc.format.extent10481 - 10491
dc.languageeng
dc.language.isoeng
dc.publisherAMER CHEMICAL SOC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line, Tumor
dc.subjectHumans
dc.subjectLipids
dc.subjectGreen Fluorescent Proteins
dc.subjectRNA, Messenger
dc.subjectMicroscopy, Fluorescence
dc.subjectTransfection
dc.subjectCell Survival
dc.subjectHigh-Energy Shock Waves
dc.subjectNanoparticles
dc.subjectHEK293 Cells
dc.titleLipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves.
dc.typeJournal Article
rioxxterms.versionofrecord10.1021/acsami.8b21398
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-03-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfACS applied materials & interfaces
pubs.issue11
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.publication-statusPublished
pubs.volume11
pubs.embargo.termsNot known
icr.researchteamChromosomal Translocations and Intracellular Antibody Therapeutics
dc.contributor.icrauthorRabbitts, Terence


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0